Xinhua Pharmaceutical (Shouguang) Co., Ltd. is a large-scale enterprise wholly funded by Shandong Xinhua Pharmaceutical Co., Ltd. in July 2008 in Shouguang City. Located in Houzhen, Shouguang City, a nationally renowned "Hometown of Vegetables" by the Bohai Laizhou Bay, the company is primarily engaged in the production and operation of chemical raw materials and chemical products.

       Shandong Xinhua Pharmaceutical Co., Ltd. is a major production and export base for antipyretic and analgesic drugs in Asia, as well as a significant domestic manufacturer of anti-infective, central nervous system, hormonal, and cardiovascular and cerebrovascular drugs. Its predecessor was the Shandong Xinhua Pharmaceutical Factory, a military enterprise established in 1943.

       Xinhua Pharmaceutical Co., Ltd. mainly produces chemical raw materials, pharmaceutical preparations, chemical products, anti-corrosion chemical equipment, pharmaceutical equipment, and pharmaceutical packaging materials. With an annual production capacity of nearly 15,000 tons of chemical raw materials, and tablet, capsule, and injection production capacities of 5 billion tablets, 300 million capsules, and 200 million injections respectively, Xinhua Pharmaceutical is a listed company on the Hong Kong H-share and Shenzhen A-share markets.

       Xinhua Pharmaceutical (Shouguang) Co., Ltd. covers an area of 1,300 acres with a registered capital of 230 million RMB and a planned total investment of 3 billion RMB. Its production technology and processes are primarily supported and innovated by the parent company, Xinhua Pharmaceutical, ensuring strong technical capabilities. The company currently has 530 employees, including 350 graduates from colleges and technical schools. Starting in 2019, the parent company implemented a strategic shift, designating five key functional production bases. Xinhua Pharmaceutical (Shouguang) will focus on the development of specialty raw materials and pharmaceutical intermediates, establishing a specialty raw material production base. Future projects include the completion of a 50,000-ton neopentyl glycol and derivatives facility, the expansion and renovation of a 15,000-ton/year series of violuric acid products, and specialty raw materials and supporting projects. Xinhua Pharmaceutical's specialty raw materials, such as acetamide and stibogluconate, have long been designated as national key emergency reserve medications, making significant contributions to global emergency pandemic response. Upon completion, these projects are expected to generate annual sales revenue of over 3 billion RMB and profits and taxes exceeding 400 million RMB.

       As a newly established modern large-scale enterprise, Xinhua Pharmaceutical (Shouguang) Co., Ltd. has consistently adhered to a people-oriented employment mechanism that values talent, collective effort, and shared development, along with a development philosophy of "technology first, quality wins." The company is committed to becoming an outstanding enterprise in the northern Shouguang region.